Mereo BioPharma Provides Update on Pipeline Progress and Cor

Phase 3 portion of Orbit Study and Phase 3 Cosmic Study of setrusumab for treatment of Osteogenesis Imperfecta conducted by partner Ultragenyx expected to complete enrollment around the end of 1Q...

Related Keywords

United States , London , City Of , United Kingdom , Mark Dransfield , Christine Fox , Lee Roth , Mereo Biopharma , Denise Scots Knight , Ultragenyx Pharmaceutical Inc , Translational Sciences , Division Of Pulmonology , Nasdaq , Mereo Biopharma Group , Industry Program , Exchange Commission , National Center , United States Securities Exchange , National Institutes Of Health , Division Of Clinical Outcome Assessment , University Of Alabama At Birmingham , Astraeus , Orbit Study , Osteogenesis Imperfecta , Additional Phase , Deficiency Associated Lung Disease , Biopharma Group , Chief Executive Officer , Deficiency Associated Lung , Global Phase , Ultragenyx Pharmaceutical , Critical Care , Clinical Outcome Assessment , Patient Reported Outcome , Respiratory Questionnaire , Total Score , Advancing Translational Sciences , National Institutes , Professor Mark Dransfield , License Agreement , Runway Guidance , Financial Reporting , United States Securities Act , United States Securities Exchange Act , Annual Report , Biopharma Contacts , Chief Executive , Chief Financial , Investor Relations Adviser , Markets ,